Opinion|Videos|April 24, 2025
Future of Bispecifics and CAR T in R/R MM
Panelists discuss how the preliminary results from the IMMagine-1 trial (ASH 2024, abstract #1031) on anitocabtagene autoleucel highlight the evolving role of bispecifics and chimeric antigen receptor (CAR) T-cell therapies in the treatment landscape for relapsed/refractory multiple myeloma (R/R MM).
Advertisement
Episodes in this series
Video content above is prompted by the following:
Future of Bispecifics and CAR T in R/R MM:
The treatment landscape for R/R MM is evolving, with CAR T therapies and bispecific antibodies emerging as key modalities:
- CAR T Therapy: Anitocabtagene autoleucel adds to the growing body of evidence supporting personalized, deep, and durable responses in R/R MM, although accessibility and manufacturing time remain challenges.
- Bispecific Antibodies: Off-the-shelf alternatives offer flexibility and repeated dosing advantages, with ongoing trials optimizing sequencing and combination strategies.
Future research will focus on sequencing, combination approaches, and bridging strategies to enhance outcomes and accessibility in R/R MM treatment.
Advertisement
Related to this article
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
5